TC Biopharm (Holdings) (TCBPY) AI Stock Analysis

• Market Cap: $191.31K
• Dividend Yield: N/A
• Average Volume (3M): 9.03K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.20
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 41
• Sector: Healthcare
• Sector Strength: 44
• Industry: Biotechnology
• EPS (TTM): N/A
• Shares Outstanding: 2,103,054
• 10 Day Avg. Volume: 3,904
• 30 Day Avg. Volume: 9,033
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): 0.00
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 38 Underperform
• Price Target: ―

TC Biopharm's overall score is primarily impacted by its weak financial performance, characterized by declining revenues and negative cash flow. Technical analysis indicates bearish momentum, while the absence of valuation metrics and earnings call information limits positive insights. The stock's financial instability and operational inefficiencies are major concerns.

TC Biopharm (Holdings) Business Overview & Revenue Model

Company Description

TC Biopharm (Holdings) Plc Sponsored ADR (TCBP) is a biotechnology company focused on developing innovative cell-based therapies for the treatment of cancer and other serious diseases. The company operates in the biopharmaceutical sector and is dedicated to leveraging its expertise in gamma-delta T cell technology to create effective immunotherapies. TC Biopharm's core products include novel therapies that aim to harness the body's immune system to target and eliminate cancer cells, providing patients with potentially transformative treatment options.

How the Company Makes Money

TC Biopharm makes money primarily through the development and commercialization of its cell-based therapeutic products. The company's revenue streams include licensing agreements, where it partners with larger pharmaceutical companies to co-develop or distribute its therapies, thereby receiving upfront payments, milestone payments, and royalties on sales. Additionally, TC Biopharm may engage in research collaborations or receive grants and funding from governmental or non-governmental organizations to support its research and development activities. The success of its revenue model relies heavily on the successful advancement of its therapies through clinical trials and regulatory approval processes.

TC Biopharm (Holdings) Financial Statement Overview

Summary

Income Statement

Balance Sheet

Cash Flow

Breakdown
Income Statement
Total Revenue
Gross Profit
EBITDA
Net Income
Balance Sheet
Total Assets
Cash, Cash Equivalents and Short-Term Investments
Total Debt
Total Liabilities
Stockholders Equity
Cash Flow
Free Cash Flow
Operating Cash Flow
Investing Cash Flow
Financing Cash Flow

TC Biopharm (Holdings) Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 0.26
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TCBPY, the sentiment is Positive. The current price of 0.26 is below the 20-day moving average (MA) of 0.30, below the 50-day MA of 0.31, and below the 200-day MA of 12.08, indicating a neutral trend. The MACD of -0.01 indicates Negative momentum. The RSI at 54.80 is Neutral, neither overbought nor oversold. The STOCH value of 32.26 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TCBPY.

TC Biopharm (Holdings) Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GILD	71 Outperform	$136.65B	22.88	32.51%	2.88%	4.63%	1144.01%
IMTX	58 Neutral	$745.10M	53.85	-4.52%	―	92.31%	78.17%
Sector *	52 Neutral	$7.47B	-0.04	-63.86%	2.34%	16.17%	0.25%
BLUE	51 Neutral	$48.67M	―	-546.55%	―	127.51%	56.94%
FATE	50 Neutral	$129.54M	―	-49.23%	―	105.85%	22.13%
ADAP	48 Neutral	$69.62M	―	-273.36%	―	883.05%	62.93%
TCBPY	38 Underperform	$191.31K	―		―	―	―